UK Markets closed

Oryzon Genomics S.A. (0RDB.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
3.0250-0.0350 (-1.14%)
At close: 8:47AM BST
Full screen
Previous close3.0600
Open3.0400
Bid0.0000 x 0
Ask0.0000 x 0
Day's range3.0250 - 3.0400
52-week range3.0250 - 3.0400
Volume6
Avg. volumeN/A
Market cap110.525M
Beta (5Y monthly)0.99
PE ratio (TTM)N/A
EPS (TTM)-0.0640
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    ORYZON Reports Results and Corporate Update for Quarter Ended September 30, 2021

    MADRID, Spain and CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the third quarter of 2021 and provided an update on recent developments. Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued to make vigorous progress on our clinical pipeline this quar

  • Globe Newswire

    ORYZON enrolls first patient in the US in PORTICO, a Phase IIb clinical trial with vafidemstat in Borderline Personality Disorder

    PORTICO already recruiting in several European countries MADRID, Spain and CAMBRIDGE, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the enrollment of the first patient in the US in its Phase IIb clinical trial with vafidemstat, a selective inhibitor of the epigenetic target LSD1, in Borderline Personali

  • Globe Newswire

    ORYZON presents safety and efficacy data of vafidemstat from the Phase II SATEEN trial in multiple sclerosis at ECTRIMS-2021

    Long-term vafidemstat treatment was safe and well tolerated with drug exposures up to 2 yearsAnti-inflammatory activity observed in vafidemstat-treated patientsSATEEN was a pilot, small scale, trial not powered to get definitive efficacy data MADRID, Spain and CAMBRIDGE, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, pr